#lodi646
Stock market today: Wall Street gains ground as it heads for a winning weekKathmandu, Dec 26: The government has formed a recommendation committee for the appointment of Chairperson of Nepal Insurance Authority. A meeting of the Council of Ministers held on Tuesday formed such committee under the coordination of a National Planning Commission member, Minister for Communications and Information Technology Prithvi Subba Gurung said on Thursday announcing the decisions of the cabinet meeting. Finance Secretary and Joyti Chandra Ojha are the members in the committee. Likewise, the cabinet meeting has formed a recommendation committee under the chair of Chairman of Public Service Commission for the appointment of members in the Teachers Service Commission. Vice Chancellor of Tribhuvan University and Secretary at the Ministry of Education, Science and Technology are the members of the committee. Minister Gurung said that the cabinet meeting has decided to fix penalty, as per the Chapter 3 of the Money Laundering Prevention Act 2008, to those involved in misappropriation, human smuggling, Hundi, virtual currency, match fixing and embezzlement and operation of casinos without taking license. Furthermore, the meeting has given theoretical permission to formulate a bill on facilities to the former VIPs. According to Minister Gurung, the cabinet meeting appointed members of the National Sports Council. The appointees include Shanti Kumari Chaudhary (Jhapa), Ananda Kumar Jha (Saptari), Suwarna Shrestha (Lalitpur), Kamal Bahadur Bhattarai (Sarlahi), Himal Kumar Shrestha (Gulmi), Nanda Basyal (Surkhet), Jagat Singh Dhami (Darchula) and Bhan Bahaadur Chand (Kanchanpur). The cabinet meeting also promoted Joint Secretary Madhu Prasad Bhetuwal to the post of Secretary and deputed him at the Water and Energy Commission Secretariat, Minister Gurung said.(RSS)
In the end, whether the underdogs emerge victorious or Real Madrid prove too strong, one thing is certain – this match will be remembered for years to come as a symbol of the passion, drama, and excitement that football can bring to fans around the world. Let the countdown begin as we prepare to witness a spectacle that will capture the hearts and minds of football lovers everywhere.THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE Amgen
BE Semiconductor Industries’ stock saw a dramatic increase in short interest during December. By December 15th, short interest had ballooned to 2,400 shares, marking a staggering rise of 2,300% compared to just 100 shares at the end of November. Given the average daily trading volume of 4,900 shares, this equates to a days-to-cover ratio of 0.5 days. Current Stock Performance On the recent trading day, BE Semiconductor’s shares climbed by $3.91, settling at $140.85. This rise occurred with 1,557 shares exchanged, somewhat lower than the typical volume of 2,324 shares. Over the past year, the stock has experienced notable volatility, with a low of $105.53 and a high of $195.34. Its recent moving averages indicate a moderate trend, with the 50-day average at $121.24 and the 200-day average at $134.31. Financially, the company boasts a robust current ratio of 6.86 and a debt-to-equity ratio of 1.13, supported by a market cap of $10.21 billion. Earnings Highlights BE Semiconductor recently disclosed its quarterly earnings, revealing a $0.65 earnings per share. The firm showed a strong return on equity at 39.36% and a significant net margin of 28.93%, with revenues reaching $172.08 million for the quarter. BE Semiconductor Industries, a global player in semiconductor assembly equipment, operates extensively in markets spanning across the US, Asia, and Europe. Despite holding a “Hold” rating, top analysts spotlight other stocks as more promising investments in the current market climate. Why BE Semiconductor Industries Might Be the Next Big Name in the Sector Key Features and Innovations BE Semiconductor Industries, known for its advancements in semiconductor assembly equipment, is steadily climbing the ranks due to its innovative technologies. These innovations are aimed at meeting the growing demands of the semiconductor industry, which is pivotal in tech products from smartphones to electric vehicles. The company’s focus on sustainability is also notable, as it seeks to reduce environmental impact through efficient manufacturing practices. Their cutting-edge technologies cater extensively to high-growth areas including 5G, AI, and advanced computing, which are reshaping global economies. Financial Insights and Market Potential The recent rise in BE Semiconductor’s stock price reflects its strong financial footing, highlighted by its impressive return on equity of 39.36% and a net margin of 28.93%. These figures position the company favorably against its competitors in the industry, offering a robust outlook for investors looking for stable yet dynamic market opportunities. Despite a “Hold” rating from analysts, the market cap of $10.21 billion showcases its standing as a significant player with substantial growth potential. Comparisons and Market Analysis Within the semiconductor sector, BE Semiconductor stands out with its solid financial health compared to peers, driven by its sizable current ratio of 6.86. Nevertheless, the market is highly competitive with other emerging technologies and companies that are attractive to investors. A comparison with competitors reveals that while BE Semiconductor’s operational strength is impressive, the market generally views other stocks as higher-risk with potentially higher rewards. Limitations and Challenges Despite its achievements, BE Semiconductor faces ongoing challenges like market volatility and competition from both well-established and emerging firms. Its stock’s past variance, from $105.53 to a peak of $195.34, underscores the sector’s inherent unpredictability, potentially deterring risk-averse investors. Consequently, navigating these fluctuations while capitalizing on trends such as green manufacturing and artificial intelligence integration remains crucial for sustained success. Future Predictions and Trends Looking forward, the company is poised to leverage cross-continental demands in the US, Asia, and Europe, where semiconductor needs are rapidly expanding. The global transition toward digital and electric technologies offers a fertile ground for BE Semiconductor’s innovative approaches. It is predicted that ongoing developments in 5G and quantum computing will further boost demand for BE Semiconductor’s cutting-edge products, solidifying its position in the future tech landscape. For more information about BE Semiconductor Industries, visit their official website .Published 23:07 IST, December 26th 2024 Manmohan Singh passed away on Thursday evening, December 26, at AIIMS Delhi. New Delhi: Former Prime Minister Dr. Manmohan Singh passed away on Thursday evening, December 26, at AIIMS Delhi. He was 92 years old. Singh, breathed his last at 9:51 PM due to age-related health complications. The nation united in grief, with tributes pouring in from across the political spectrum and beyond. Leaders, economists, and citizens alike hailed him as a visionary statesman, a distinguished economist, and a man of impeccable integrity. Prime Minister Modi Leads Tributes Prime Minister Narendra Modi expressed his sorrow in an X post, stating: "India mourns the loss of one of its most distinguished leaders, Dr. Manmohan Singh Ji. Rising from humble origins, he became a respected economist and served in various government positions, leaving a lasting imprint on our economic policies. As our Prime Minister, he made extensive efforts to improve people’s lives." Vice President Jagdeep Dhankhar called Singh the "architect of India's economic liberalization," recalling his courage in steering the nation through its most challenging economic transitions. "Deeply pained to learn about the passing of Dr. Manmohan Singh Ji. A Padma Vibhushan awardee, he boldly opened new pathways for growth and prosperity." Congress President Mallikarjun Kharge described Singh as a “visionary statesman” whose policies lifted millions out of poverty and transformed India’s middle class. "Undoubtedly, history shall judge you kindly, Dr. Manmohan Singh Ji!" he added. Union Home Minister Amit Shah acknowledged Singh’s vital contributions as an economist and leader. "Dr. Manmohan Singh played an important role in the governance of the country. May Waheguru grant peace to his soul and give strength to his family to bear this grief," he said. Defence Minister Rajnath Singh emphasized Singh’s role in rebuilding India’s economy during difficult times. "He was widely respected for his service and intellect. His contribution to India’s progress will always be remembered," he remarked. Congress leader Priyanka Gandhi Vadra hailed Singh as a beacon of honesty and courage. "Few people in politics inspire the kind of respect that Sardar Manmohan Singh Ji did. His honesty and steadfast commitment to the nation will forever stand tall," she wrote in her tribute. BJP national president JP Nadda called Singh's death an “immense loss for the nation,” while J&K CM Omar Abdullah referred to him as an “intellectual giant and a thorough gentleman.” Get Current Updates on India News , Entertainment News along with Latest News and Top Headlines from India and around the world. Updated 23:07 IST, December 26th 2024None
In addition to its impressive technical capabilities, Sora also boasts a user-friendly interface that makes it easy for creators of all skill levels to harness the power of AI-driven video generation. Whether you are a seasoned professional or an aspiring filmmaker, Sora offers a seamless and intuitive workflow that simplifies the video creation process.From wealth and success to murder suspect, the life of Luigi Mangione took a hard turn
In conclusion, while real estate assets continue to be a valuable "anchor" in investment portfolios, the pricing mechanisms of public REITs remain a work in progress. By standardizing valuation metrics, enhancing disclosure requirements, and improving risk management practices, the public REITs market can become more efficient and transparent, providing investors with a better understanding of the true value of real estate assets. As the demand for real estate investments continues to grow, ensuring a robust pricing mechanism for public REITs is essential to maintaining market integrity and investor confidence.Industry analysts and experts have been closely tracking TSMC's development of 2nm chips, recognizing the potential impact that this cutting-edge technology could have on a wide range of applications, from mobile devices to artificial intelligence and beyond. The high yield rate achieved by TSMC on its 2nm chips not only signals the company's technological prowess but also paves the way for a new era of semiconductor innovation.Giles' 25 help UNC Greensboro beat N.C. A&T 67-55
Recently, Google made a groundbreaking announcement in the field of quantum computing by unveiling their latest quantum chip called "Willow". The new quantum chip represents a monumental leap forward in the quest for powerful quantum computing capabilities, as it successfully tackled a major challenge that has persisted for over 30 years. With the ability to perform calculations equivalent to 10^25 years of supercomputing in just a fraction of the time, the Willow chip is poised to revolutionize the landscape of computational science and technology.Beirut: Syrian rebels announced they had gained full control over the key city of Homs early on Sunday after only a day of fighting, leaving President Bashar al-Assad’s 24-year rule dangling by a thread as insurgents marched on the capital, Damascus. Thousands of Homs residents poured onto the streets after the army withdrew from the central city, dancing and chanting “Assad is gone, Homs is free” and “Long live Syria and down with Bashar al-Assad”. A giant portrait of Bashar al-Assad sits on a building in Damascus. Credit: AP Rebels fired guns into the air in celebration, and youths tore down posters of the Syrian president, whose territorial control has collapsed in a dizzying week-long retreat by the military. The fall of Homs gives the insurgents control over Syria’s strategic heartland and a key highway crossroads, severing Damascus from the coastal region that is the stronghold of Assad’s Alawite sect and where his Russian allies have a naval base and air base. Homs’ capture is also a powerful symbol of the rebel movement’s dramatic comeback in the 13-year-old conflict. Swaths of Homs were destroyed by gruelling siege warfare between the rebels and the army years ago. The fighting ground down the insurgents, who were forced out. Hayat Tahrir al-Sham commander Abu Mohammed al-Golani, the main rebel leader, called the capture of Homs a historic moment and urged fighters not to harm “those who drop their arms”. Syrian opposition fighters on a seized Syrian air force fighter plane at the Hama military airport on Friday. Credit: AP Rebels freed thousands of detainees from the city prison. Security forces left quickly after burning their documents. Syrian rebel commander Hassan Abdul Ghani said in a statement early on Sunday that operations continued to “completely liberate” the countryside around Damascus and rebel forces were looking towards the capital. In one suburb, a statue of Assad’s father, the late former president Hafez al-Assad, was toppled and torn apart. The Syrian army said it was reinforcing around Damascus, and state television reported on Saturday that Assad remained in the city. People arrive at the Jordanian side of the border as others wait in their cars on Saturday, after a ban on crossings into Syria. Credit: Getty Images The lightning rebel advance suggests Assad’s government could fall within the next week, US and other Western officials said. Since the rebels’ sweep into Aleppo a week ago , government defences have crumbled at a dizzying speed as insurgents seized a string of major cities and rose in places where the rebellion had long seemed over. The twin threats to Damascus and the strategically vital city of Homs now pose an existential danger to the Assad dynasty’s five-decade reign over Syria and the continued influence in the country of its main regional backer, Iran. The rebels’ moves around Damascus, reported by an opposition war monitor and a rebel commander, came after the Syrian army withdrew from much of the southern part of the country, leaving more areas, including several provincial capitals, under the control of opposition fighters. Syrian President Bashar al-Assad is backed by Russia and Iran, but both are bogged down in separate conflicts. Credit: Saudi Press Agency/AP The advances in the past week were among the largest in recent years by opposition factions led by a group that has its origins in al-Qaeda and is considered a terrorist organisation by the US and the United Nations. In their push to overthrow Assad’s government, the insurgents, led by the Hayat Tahrir al-Sham group, or HTS, have met little resistance from the Syrian Army. The UN’s special envoy for Syria, Geir Pedersen, on Saturday called for urgent talks in Geneva to ensure an “orderly political transition”. Speaking to reporters at the annual Doha Forum in Qatar, Pedersen said the situation in Syria was changing by the minute. Russian Foreign Minister Sergey Lavrov, whose country is Assad’s chief international backer, said he felt “sorry for the Syrian people”. In Damascus, people rushed to stock up on supplies. Thousands went to Syria’s border with Lebanon, trying to leave the country. Many shops in the city were shuttered, a resident told the Associated Press, and those still open had run out of staples such as sugar. Some were selling items at three times the normal price. “The situation is very strange. We are not used to that,” the resident said, insisting on anonymity, fearing retributions. “People are worried whether there will be a battle [in Damascus] or not.” It was the first time that opposition forces reached the outskirts of Damascus since 2018 when Syrian troops recaptured the area following a years-long siege. The UN said it was moving non-critical staff outside the country as a precaution. Assad rumours Syria’s state media denied social media rumours that Assad had left the country, saying the president was performing his duties in Damascus. Assad has had little, if any, help from his allies. Russia is busy with its war in Ukraine, and Lebanon’s Hezbollah, which at one point sent thousands of fighters to shore up Assad’s forces, has been weakened by a year-long conflict with Israel. Iran has had its proxies across the region degraded by regular Israeli airstrikes. US President-elect Donald Trump on Saturday posted on social media that the US should avoid engaging militarily in Syria. A Syrian opposition fighter holds a rocket launcher in front of the provincial government office. Credit: AP Pedersen said a date for talks in Geneva on implementing a 2015 UN resolution calling for a Syrian-led political process would be announced later. The resolution calls for the establishment of a transitional governing body, followed by the drafting of a new constitution and ending with UN-supervised elections. Foreign ministers and senior diplomats from eight key countries, including Saudi Arabia, Russia, Egypt, Turkey and Iran, along with Pedersen, gathered on the sidelines of the Doha summit on Saturday to discuss the situation. No details were immediately available. The insurgents’ march Rami Abdurrahman, who heads the UK-based Syrian Observatory for Human Rights, an opposition war monitor, said insurgents were in the Damascus suburbs of Maadamiyah, Jaramana and Daraya. Opposition fighters were also marching toward the Damascus suburb of Harasta, he said. An insurgent commander, Hassan Abdul Ghani, posted on the Telegram messaging app that opposition forces had begun the “final stage” of their offensive by encircling Damascus. Syrian rebel leader Abu Mohammed al-Golani. Credit: Al Jazeera HTS controls much of north-west Syria and, in 2017, set up a “salvation government” to run daily affairs in the region. In recent years, HTS leader Abu Mohammed al-Golani has sought to remake the group’s image, cutting ties with al-Qaeda, ditching hardline officials and vowing to embrace pluralism and religious tolerance. Syria’s military, meanwhile, sent large numbers of reinforcements to defend the key central city of Homs, Syria’s third-largest, as insurgents approached its outskirts. The shock offensive began on November 27, during which rebel fighters captured the northern city of Aleppo, Syria’s largest, and the central city of Hama, the country’s fourth-largest city. Opposition activists on Friday said insurgents entered Palmyra, which is home to invaluable archaeological sites that had been in government hands since being taken from the Islamic State group in 2017. To the south, Syrian troops left much of the province of Quneitra, including the main Baath City, activists said. The Syrian Observatory said government troops had withdrawn from much of the two southern provinces and were sending reinforcements to Homs, where a battle loomed. If the insurgents were to capture Homs, they would cut the link between Damascus, Assad’s seat of power, and the coastal region where the president enjoys wide support. The army said in a statement that it had carried out redeployment and repositioning in Sweida and Daraa after its checkpoints came under attack by “terrorists”. The army said it was setting up a “strong and coherent defensive and security belt in the area”, apparently to defend Damascus from the south. The Syrian government has referred to opposition gunmen as terrorists since the conflict broke out in March 2011. Diplomacy in Doha The foreign ministers of Iran, Russia and Turkey, meeting in Qatar, called for an end to the hostilities. Turkey is the main backer of the rebels. Qatar’s top diplomat, Sheikh Mohammed bin Abdulrahman Al Thani, criticised Assad for failing to take advantage of the lull in fighting in recent years to address the country’s underlying problems. “Assad didn’t seize this opportunity to start engaging and restoring his relationship with his people,” he said. Sheikh Mohammed said he was surprised by how quickly the rebels have advanced and said there was a real threat to Syria’s “territorial integrity”. He said the war could “damage and destroy what is left if there is no sense of urgency” to start a political process. AP, Reuters Get a note directly from our foreign correspondents on what’s making headlines around the world. Sign up for our weekly What in the World newsletter .Wang Chuqin, a rising star in the Chinese table tennis scene, has been showcasing impressive performances and solidifying his position as the top-ranked male player in the world. With his exceptional skills and unwavering determination, Wang has managed to maintain his lead at the pinnacle of the rankings, demonstrating his immense talent and potential for future success.
Middle East latest: Israeli strikes in Gaza kill more than 50 people, including kids
Bankwell financial director Blake Drexler acquires $460 in stockThe continuing prominence of the business value of audio has provided favorable conditions for the upcoming IPO of Himalaya, offering a promising outlook for the company's future growth and success.
The Value Anchor of Real Estate Assets
Is Tomorrow A Holiday Trends After Death Of Former PM Manmohan Singh
China A-shares surged during the opening of trading on Monday, with all three major indexes opening higher and experiencing substantial gains. The Shanghai Composite Index, the Shenzhen Component Index, and the ChiNext Index all exhibited strong performance, signaling a bullish start to the trading day.
Nvidia, known for its high-performance graphics processing units (GPUs) and artificial intelligence technologies, has a significant presence in the Chinese market. The company's products are widely used in gaming, data centers, and autonomous vehicles, making it a key player in China's rapidly evolving tech landscape. However, Nvidia's dominance in certain market segments has raised concerns among regulators about potential anti-competitive practices.
THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE Amgen